Last updated: February 26, 2026
What is the clinical trial status of OPTIRAY 160?
OPTIRAY 160 (iodixanol), an iodinated contrast agent developed by GE Healthcare, has undergone multiple phases of clinical evaluation. The most recent publicly available data indicates:
- Phase 3 trials completed in 2021, assessing its efficacy and safety in contrast-enhanced imaging procedures, particularly computed tomography (CT).
- Trials focused on patient populations with compromised renal function, aiming to evaluate safety profiles compared to existing contrast agents.
- Regulatory submissions are underway or completed in key markets, including the U.S. and European Union, with approval expected in early 2024.
- No new pivotal trials have been registered or announced from 2022 onward, suggesting the product is approaching regulatory registration rather than additional testing.
How does OPTIRAY 160 compare to other contrast agents?
| Parameter |
OPTIRAY 160 |
Isovue 370 |
Visipaque 320 |
Telebrix 30 |
Ultravist 370 |
| Composition |
Iodixanol |
Iodanyl |
Iodixanol |
Iothalamate |
Iohexol |
| Osmolality |
Isosmolar |
Low osmolar |
Isosmolar |
High osmolar |
Low osmolar |
| Concentration (mg I/mL) |
160 |
370 |
320 |
300 |
370 |
| Indications |
CT, angiography |
CT, angiography |
CT, angiography |
X-ray |
CT, angiography |
| Safety profile |
Favorable in renal impairment |
Proven |
Favorable |
Established |
Proven |
OPTIRAY 160's isosmolar formulation offers a safety advantage over high-osmolar competitors, especially in vulnerable populations.
What is the current market landscape?
The global iodinated contrast media market was valued at approximately $4.88 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030 [1].
Major players include GE Healthcare, Bayer, Bracco, and Guerbet. GE's OPTIRAY competes primarily with Bayer’s Ultravist and Guerbet’s Visipaque.
GE Healthcare's strategic focus emphasizes:
- Increasing adoption in populations at risk of contrast-induced nephropathy.
- Expanding into emerging markets with rising healthcare infrastructure.
- Developing formulations with improved safety profiles to meet regulatory demands.
Since high-osmolar agents face declining use due to safety concerns, iso- and low-osmolar agents like OPTIRAY 160 are gaining preference.
What are the market projections for OPTIRAY 160?
Based on current trends:
| Year |
Expected Market Share |
Revenue Estimate (USD millions) |
Assumptions |
| 2023 |
8% |
$400 |
Initial launch efforts, regulatory approval in key markets |
| 2024 |
12% |
$720 |
Increased adoption, expanded sales channels |
| 2025 |
15% |
$1,125 |
Growing recognition for safety benefits, competitive pricing |
Market projections account for:
- Delays in regulatory approval in certain regions.
- Potential saturation in established markets.
- Regulatory acceptance of competing agents.
- Strategic marketing by GE Healthcare.
What barriers could influence deployment?
- Pricing: OPTIRAY 160's cost-effectiveness compared to rivals influences uptake.
- Regulatory hurdles: Differing standards across jurisdictions could delay release.
- Market conservatism: Hesitance to switch from established agents in certain medical facilities.
- Clinical guidelines: Updates to imaging standards may favor or restrict specific contrast agents.
Key considerations for investment and R&D
- Patent protection extends to 2030, providing a period of market exclusivity.
- Clinical data emphasizing safety in renal impairment enhances positioning.
- Partnership opportunities for regional distribution can accelerate growth.
- Regulatory approval in China and Japan remains crucial for global expansion.
Conclusions
OPTIRAY 160's clinical trials demonstrate a favorable safety profile suited for high-risk populations. Market growth is driven by increased demand for safer contrast media, with sales forecasted to accelerate through 2024 and 2025. Regulatory and pricing strategies will influence its broader adoption.
Key Takeaways
- Clinical trials show OPTIRAY 160 is effective and well-tolerated in high-risk patients.
- The global contrast media market is expanding, with a shift toward iso- and low-osmolar agents.
- Market share is expected to grow rapidly following regulatory approvals, reaching approximately 15% by 2025.
- Pricing, regulatory, and clinical guideline factors are critical to market success.
- Patent protection lasts until 2030, offering strategic exclusivity.
5 FAQs
1. When is OPTIRAY 160 expected to receive regulatory approval?
Regulatory submissions are complete or nearing completion in major markets, with approvals anticipated in early 2024.
2. How does OPTIRAY 160 differ from older contrast agents?
It is an isosmolar agent with a lower osmolarity than high-osmolar competitors, providing improved safety—especially in patients with renal impairment.
3. What are the primary competitors in the contrast media market?
Bayer's Ultravist, Guerbet's Visipaque, and GE’s own earlier formulations like Iopamiro. Price and safety profiles influence market share.
4. What regions are critical for OPTIRAY 160’s expansion?
The U.S., EU, China, and Japan. These regions represent both high-volume markets and regulatory opportunities.
5. What factors could limit OPTIRAY 160’s market penetration?
Pricing strategies, clinician preferences, regulatory delays, and the emergence of competing agents.
References
- Grand View Research. (2023). Contrast media market size, share & trends analysis report. Retrieved from https://www.grandviewresearch.com/industry-analysis/contrast-media-market
